Kadmonnow A Part Of Sanofiwas A Biopharmaceutical Company Dedicated To Developing Therapies For Diseases With Significant Unmet Medical Needsfounded In 2009 By Samuel Dwaksalkadmon Focused On Innovative Treatments For Immune Mediated And Fibrotic Diseasesoncologyand Transplant Related Conditionsone Of Its Key Products Is Rezurocka Belumosudil A First In Class Rho Associated Coiled Coil Kinase 2Rock2Inhibitor Approved By The Fda For Chronic Graft Versus Host Diseasecgvhdin Patients Aged 12 And Older Who Have Not Responded To Prior Therapiesfollowing Its Acquisition By Sanofi In 2021Kadmon S Operations And Productsincluding Rezurocka Have Been Integrated Into Sanofiae S Broader Portfolioenhancing Its Offerings In Transplant Care And Other Therapeutic Areas
No conferences found for this company.
| Company Name | Kadmon Corporation Llc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
